Sveriges Riksbank
24.2.2021 06:22:22 CET | Globenewswire | Press release
| Auction | Auction results |
| Auction date | 2021-02-23 |
| Maturity | 2024 |
| Tendered volume, SEK mln | 1000 +/- 1000 |
| Offered volume, SEK mln | 101 |
| Volume bought, SEK mln | 101 |
| Number of bids | 2 |
| Number of accepted bids | 2 |
| Quarter | Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 |
| Offered volume, SEK mln | 0 | 0 | 0 | 0 |
| Volume bought, SEK mln | 0 | 0 | 0 | 0 |
| Number of bids | 0 | 0 | 0 | 0 |
| Number of accepted bids | 0 | 0 | 0 | 0 |
| Average DM | - | - | - | - |
| Lowest accepted DM | - | - | - | - |
| Highest DM | - | - | - | - |
| Accepted at lowest DM | - | - | - | - |
| Quarter | Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 |
| Offered volume, SEK mln | 50 | 0 | 51 | 0 |
| Volume bought, SEK mln | 50 | 0 | 51 | 0 |
| Number of bids | 1 | 0 | 1 | 0 |
| Number of accepted bids | 1 | 0 | 1 | 0 |
| Average DM | -3.25 | - | -4 | - |
| Lowest accepted DM | -3.25 | - | -4 | - |
| Highest DM | -3.25 | - | -4 | - |
| Accepted at lowest DM | 100 | - | 100 | - |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
HENLEY & PARTNERS GROUP HOLDINGS LTD2.10.2026 18:54:53 CEST | Press release
Henley & Partners - Argentina Announces New Citizenship by Investment Program
Unlimit Group A/S2.10.2026 18:05:13 CEST | Pressemeddelelse
Unlimit Group A/S: Indkaldelse til ekstraordinær generalforsamling
BONDUELLE2.10.2026 18:00:00 CEST | Press release
Bonduelle - 2025-2026 Annual results: The Bonduelle Group demonstrates its resilience, ending fiscal year 2025-2026 with stable sales and profitability
Biogen Inc.2.10.2026 17:20:00 CEST | Press release
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Netcompany Group A/S2.10.2026 17:12:00 CEST | Press release
Major shareholder announcement
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom